Quick Answer
Keros Therapeutics, Inc. reported Operating Income Loss of $67.57 million for the year ending 2025.
- Keros Therapeutics, Inc. showed an increase of +132.0% in Operating Income Loss from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$2.86 million | Q2 2019: -$2.65 million | Q3 2019: -$2.33 million | Q1 2020: -$10.50 million | Q2 2020: -$10.91 million | Q3 2020: -$11.95 million | Q1 2021: -$15.77 million | Q2 2021: -$15.54 million | Q3 2021: -$20.20 million | Q1 2022: -$24.13 million | Q2 2022: -$30.73 million | Q3 2022: -$27.98 million | Q1 2023: -$38.87 million | Q2 2023: -$41.34 million | Q3 2023: -$43.28 million | Q1 2024: -$48.48 million | Q2 2024: -$50.44 million | Q3 2024: -$58.66 million | Q1 2025: $152.04 million | Q2 2025: -$39.82 million | Q3 2025: -$15.38 million.
- Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Operating Income Loss has grown by 739.7%.
- Historical annual values: Fiscal year 2025: $67.57 million | Fiscal year 2024: -$210.83 million | Fiscal year 2023: -$169.94 million | Fiscal year 2022: -$114.79 million | Fiscal year 2021: -$56.37 million | Fiscal year 2020: -$46.66 million | Fiscal year 2019: -$10.56 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: